CoChat

Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo

Open access
Toki, Shinji, Goleniewska, Kasia, Reiss, Sara, Zhang, Jian, Bloodworth, Melissa H., Stier, Matthew T., Zhou, Weisong, Newcomb, Dawn C., Ware, Lorraine B., Stanwood, Gregg D., Galli, Aurelio, Boyd, Kelli L., Niswender, Kevin D., Peebles, R. Stokes · 2018 · Journal of Allergy and Clinical Immunology
Cited by 104

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background: IL‐33 is one of the most consistently associated gene candidates for asthma identified by using a genome‐wide association study. Studies in mice and in human cells have confirmed the importance of IL‐33 in inducing type 2 cytokine production from both group 2 innate lymphoid cells (ILC2s) and TH2 cells. However, there are no pharmacologic agents known to inhibit IL‐33 release from airway cells. Objective: We sought to determine the effect of glucagon‐like peptide 1 receptor (GLP‐1R) signaling on aeroallergen‐induced airway IL‐33 production and release and on innate type 2 airway inflammation. Methods: BALB/c mice were challenged intranasally with Alternaria extract for 4 consecutive days. GLP‐1R agonist or vehicle was administered starting either 2 days before the first Alternaria extract challenge or 1 day after the first Alternaria extract challenge. Results: GLP‐1R agonist treatment starting 2 days before the first Alternaria extract challenge decreased IL‐33 release in the bronchoalveolar lavage fluid and dual oxidase 1 (Duox1) mRNA expression 1 hour after the first Alternaria extract challenge and IL‐33 expression in lung epithelial cells 24 hours after the last Alternaria extract challenge. Furthermore, GLP‐1R agonist significantly decreased the number of ILC2s expressing IL‐5 and IL‐13, lung protein expression of type 2 cytokines and chemokines, the number of perivascular eosinophils, mucus production, and airway responsiveness compared with vehicle treatment. GLP‐1R agonist treatment starting 1 day after the first Alternaria extract challenge also significantly decreased eosinophilia and type 2 cytokine and chemokine expression in the airway after 4 days of Alternaria extract challenge. Conclusion: These results reveal that GLP‐1R signaling might be a therapy to reduce IL‐33 release and inhibit the ILC2 response to protease‐containing aeroallergens, such as Alternaria. Graphical abstract: Figure. No caption available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2017.11.043

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 104

Metadata

Authors
Toki, S., Goleniewska, K., Reiss, S., Zhang, J., Bloodworth, M. H., Stier, M. T., Zhou, W., Newcomb, D. C., Ware, L. B., Stanwood, G. D., Galli, A., Boyd, K. L., Niswender, K. D., & Peebles, R. S.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2018-11
Volume
142
Issue
5
Pages
1515-1528.e8
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2784233170
Cited by
104
References
18
FWCI
3.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.